Wall Street Zen Upgrades Sanara MedTech (NASDAQ:SMTI) to Buy

Sanara MedTech (NASDAQ:SMTI) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

Other equities analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of Sanara MedTech in a report on Monday, January 26th. Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $36.00.

Sanara MedTech Stock Performance

Shares of NASDAQ:SMTI opened at $16.96 on Friday. The firm’s 50 day simple moving average is $19.99 and its 200 day simple moving average is $24.30. Sanara MedTech has a fifty-two week low of $16.05 and a fifty-two week high of $35.95. The company has a market capitalization of $155.52 million, a price-to-earnings ratio of -4.01 and a beta of 1.04. The company has a debt-to-equity ratio of 7.75, a current ratio of 1.80 and a quick ratio of 1.59.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. The firm had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million. As a group, sell-side analysts forecast that Sanara MedTech will post -1.1 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its holdings in shares of Sanara MedTech by 351.7% in the third quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after buying an additional 1,171 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Sanara MedTech by 78.1% during the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock worth $78,000 after acquiring an additional 1,457 shares during the period. Lazard Asset Management LLC lifted its position in Sanara MedTech by 63,100.0% in the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after acquiring an additional 3,155 shares in the last quarter. Deutsche Bank AG lifted its position in Sanara MedTech by 171.1% in the 4th quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock valued at $93,000 after acquiring an additional 2,515 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in Sanara MedTech by 44.1% in the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after purchasing an additional 973 shares during the period. Institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.